Omada Health (NASDAQ:OMDA) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Omada Health (NASDAQ:OMDA) had its price objective upped by stock analysts at Robert W. Baird from $15.00 to $25.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 4.12% from the company’s previous close.

A number of other equities research analysts have also commented on the company. Citigroup restated an “outperform” rating on shares of Omada Health in a research report on Monday, July 20th. Weiss Ratings cut shares of Omada Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, July 13th. BTIG Research increased their price objective on Omada Health from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. Citizens Jmp lifted their price objective on Omada Health from $21.00 to $27.00 and gave the company a “market outperform” rating in a research report on Monday, July 20th. Finally, Wells Fargo & Company boosted their target price on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.75.

Omada Health Stock Down 3.9%

Shares of Omada Health stock opened at $24.01 on Wednesday. Omada Health has a 12-month low of $10.28 and a 12-month high of $26.92. The firm has a market capitalization of $1.47 billion, a PE ratio of 480.20 and a beta of 1.73. The stock’s fifty day moving average is $20.61 and its 200-day moving average is $16.32.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. The company had revenue of $87.83 million during the quarter, compared to analysts’ expectations of $80.93 million. Analysts expect that Omada Health will post -0.01 EPS for the current year.

Insider Buying and Selling

In other Omada Health news, CFO Steven L. Cook sold 33,000 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $19.89, for a total transaction of $656,370.00. Following the transaction, the chief financial officer owned 133,359 shares in the company, valued at $2,652,510.51. This trade represents a 19.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Sean P. Duffy sold 25,886 shares of Omada Health stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $22.68, for a total transaction of $587,094.48. Following the completion of the transaction, the chief executive officer directly owned 411,861 shares in the company, valued at approximately $9,341,007.48. This represents a 5.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 227,976 shares of company stock worth $4,701,095 over the last three months. 6.38% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OMDA. Raymond James Financial Inc. acquired a new stake in shares of Omada Health in the second quarter valued at about $32,000. Bellevue Group AG boosted its stake in Omada Health by 0.7% during the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after purchasing an additional 1,791 shares during the period. Quarry LP bought a new stake in Omada Health during the 4th quarter valued at approximately $29,000. Barclays PLC grew its holdings in Omada Health by 14.6% in the 4th quarter. Barclays PLC now owns 14,850 shares of the company’s stock valued at $234,000 after buying an additional 1,888 shares during the last quarter. Finally, TD Waterhouse Canada Inc. bought a new position in Omada Health in the 4th quarter worth approximately $32,000.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.